This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie policy for more information on the cookies we use and how to delete or block them.
Due to the COVID-19 pandemic and potential impact of the impending flu season, Lumos Diagnostics, a Planet Innovation company, is working with the Victorian Government to demonstrate the benefits and impact that the FebriDx® test may deliver as an acute respiratory infection (ARI) patient triage tool in the Australian healthcare system.
Any GPs, emergency departments or other healthcare professionals interested in participating in this free pilot should register their interest on our FebriDx pilot webpage.
FebriDx is a 10-minute point-of-care fingerstick test that helps differentiate viral infections that may necessitate isolation, from bacterial infections that require antibiotic therapy.
By enabling a rapid diagnostic triage at the initial visit or screening stage, the FebriDx test can assist health professionals with decision-making and may thereby help:
The test works by simultaneously detecting Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from peripheral whole blood. MxA is an intracellular protein that becomes elevated in the presence of acute viral infection and CRP is an acute-phase inflammatory protein that is elevated in the presence of clinically significant infection.
Clinical performance from two prospective multi-center US clinical trials demonstrate the FebriDx test’s high accuracy and 97-99% negative predictive value to exclude a bacterial infection.1,2
In a United Kingdom outcome study, FebriDx was shown to alter clinical management decisions in 48% of patients tested and reduced unnecessary antibiotic prescriptions by 80%3.
The FebriDx test is CE-marked and included on the ARTG (Australian Register of Therapeutic Goods). It is commercially available in Europe, Canada, Australia and various other countries.
Suraya is the Marketing Communications Manager at Planet Innovation. A former journalist, Suraya is passionate about telling engaging stories for brands that have a positive impact on the world.
A roundup of the latest news and opinions from PI.
November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.
Planet Innovation has agreed to a $A20 million strategic investment in Lumos Diagnostics, a rapid point-of-care diagnostics company.
Lumos Diagnostics and RPS Diagnostics have merged to create a full-service point-of-care diagnostic development company and support the international commercialization of FebriDx.
Seed Health, a US-based microbial sciences company, and Atmo Biosciences, a Planet Innovation early stage venture, have announced a partnership to use Atmo’s ingestible gas-sensing capsule to study the impact of probiotics on the gut microbiome.
November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.